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Abstract
Brain is a common site of breast cancer metastasis associated with significant neurologic morbidity, decreased quality of life,
and greatly shortened survival. However, the molecular and cellular mechanisms underpinning brain colonization by breast
carcinoma cells are poorly understood. Here, we used 2D-DIGE (Difference in Gel Electrophoresis) proteomic analysis
followed by LC-tandem mass spectrometry to identify the proteins differentially expressed in brain-targeting breast
carcinoma cells (MB231-Br) compared with parental MDA-MB-231 cell line. Between the two cell lines, we identified 12
proteins consistently exhibiting greater than 2-fold (p,0.05) difference in expression, which were associated by the
Ingenuity Pathway Analysis (IPA) with two major signaling networks involving TNFa/TGFb-, NFkB-, HSP-70-, TP53-, and IFNc-
associated pathways. Remarkably, highly related networks were revealed by the IPA analysis of a list of 19 brain-metastasis-
associated proteins identified recently by the group of Dr. A. Sierra using MDA-MB-435-based experimental system (Martin
et al., J Proteome Res 2008 7:908–20), or a 17-gene classifier associated with breast cancer brain relapse reported by the
group of Dr. J. Massague based on a microarray analysis of clinically annotated breast tumors from 368 patients (Bos et al.,
Nature 2009 459: 1005–9). These findings, showing that different experimental systems and approaches (2D-DIGE
proteomics used on brain targeting cell lines or gene expression analysis of patient samples with documented brain relapse)
yield highly related signaling networks, suggest strongly that these signaling networks could be essential for a successful
colonization of the brain by metastatic breast carcinoma cells.
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Introduction
Brain metastasis is one of the most feared cancer complications
affecting an estimated 10% of patients with disseminated
malignant neoplastic disease in the United States [1,2]. Even
small brain lesions can cause neurological disability, and the
median survival time for patients with brain metastasis ranges
from 3 to 6 months regardless of the type of primary cancer [3].
Approximately 15% to 20% of patients with metastatic breast
cancer will be diagnosed eventually with brain metastasis during
the course of their disease, making breast cancer the main source
of metastatic brain tumors in women [3,4]. Therefore, there is a
pressing need to gain a better understanding of the nature and
functionality of the brain colonization by metastatic breast
carcinoma cells.
It has been proposed that both the establishment and the
growth of metastases at distant sites depend on the interactions
between tumor cells and target organ microenvironment [5,6].
Consequently, a time course of metastasis at different secondary
sites may vary dramatically depending on both the type of cancer
and the characteristics of the target organ milieu. For example,
metastases from lung adenocarcinoma develop within months of
diagnosis and affect various organs including the brain [7]. In
breast cancer, however, a long period of remission often precedes
distant relapse [8,9], suggesting that breast cancer cells may
initially lack the full competence necessary for a successful
outgrowth in distant organs such as brain [2,10]. However,
because of their intrinsic robustness and plasticity, metastatic
breast carcinoma cells eventually adapt to a selective pressure of
the target organ microenvironment and activate signaling
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21977networks enabling them to thrive in the new milieu and develop
clinically relevant secondary tumors. Identifying such networks
could be of paramount importance for gaining a proper
understanding of the process of organ-specific cancer metastasis.
In this study, we sought to identify signaling networks that could
be potentially involved in breast carcinoma metastasis to the brain
using 2D-DIGE (two dimensional difference gel electrophoresis)
proteomics, a high throughout technology allowing for a
comparison of several samples on the same gel using spectrally
resolvable CyDyes to monitor the changes of thousands of proteins
at the same time [11,12]. We have used an experimental system
based on a comparative analysis of the parental MDA-MB-231
cell line (MB-231-Pa) and its brain-targeting variant MB-231-Br
[13] to identify the proteins differentially expressed between the
two cell lines. The relative abundance or differentially expressed
proteins was determined by 2D-DIGE analysis, a quantification
technique providing a great advantage of directly comparing two
samples pre-labeled with spectrally resolvable Cy3 and Cy5 dyes
and run simultaneously on the same 2D gel while normalizing
them to a third sample labeled with Cy2 and serving as an internal
standard allowing for gel-to-gel comparison. This powerful
technique was used to screen out the spots (proteins) differentially
expressed between brain seeking (MB-231-Br) and parental (MB-
231-Pa) cells and consistently exhibiting this behavior in 4
independent experiments. The subsequent mass spectrometry
(MS) analysis was used to identify the peptides digested from these
spots individually picked up from 2D gels. The additional
advantage of this experimental approach is that 2D separation
greatly reduces the complexity of the samples undergoing
subsequent MS analysis and diminishes a possibility of the
suppression of MS identification of low abundance peptides by
highly abundant proteins. We followed by the Ingenuity Pathway
Analysis (IPA) to ascertain major signaling networks associated
with these proteins and hence potentially involved in breast cancer
metastasis to the brain as well as to compare them with signaling
networks associated with a list of 19 brain metastasis associated
proteins differentially expressed in brain-targeting 435-Br1 cells
compared with parental MDA-MB-435 cells identified recently by
the group of Dr. Angels Sierra using a similar approach [14], or a
17-gene classifier associated with breast cancer brain relapse
published recently by the group of Dr. Joan Massague based on a
microarray analysis of clinically annotated breast tumors from 368
patients [2]. Our results demonstrated that, even though only 2
out of 31 proteins were in common between the MDA-MB-231-
based set identified by our group in this study and MB-435-based
set [14], and none of these proteins were present in a 17-gene
breast cancer brain relapse signature [2], they all converged on the
major signaling networks involving TNFa/TGFb-, NFkB-,
HSP70-, TP53-, and IFNa/c-related pathways. These findings,
showing that different experimental systems and approaches
Figure 1. 2D-DIGE analysis of total cellular proteins extracted from MB-231-Br brain targeting and parental MB-231-Pa cells. A and
B, 2D-DIGE analysis was carried out using 50 mg of total protein from MB-231-Pa and MB-231-Br cells labeled with Cy3 (green) and Cy5 (red),
respectively, and resolved on the same gel. Pulled sample containing equal amounts total cellular proteins from both cell lines labeled with Cy2 was
used as an internal standard (image not shown). C, Number of spots consistently exhibiting differential expression between MB-231-Pa and MB-231-
Br cells in 4 independent experiments depending on DeCyder 7.0 settings (average fold difference). D, An example of a DeCyder 7.0 2D-DIGE gel
master image. Spots consistently exhibiting average fold difference $2.00 (p,0.05 with FDR correction) between MB-231-Pa and MB-231-Br cells are
marked with red and corresponding spot numbers are indicated on the left.
doi:10.1371/journal.pone.0021977.g001
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expression analysis of patient samples with documented brain
relapse) yield highly related signaling networks associated with the
differentially expressed proteins and/or genes, suggest strongly
that these signaling networks could be essential for a successful
colonization of the brain by metastatic breast carcinoma cells.
Figure 2. A detailed analysis of 7 spots consistently exhibiting average fold difference $2.00 (p,0.05 with FDR correction) between
MB-231-Pa and MB-231-Br cells. For each indicated spot, a zoomed in image (top panel) from MB-231-Pa (left) and MB-231-Br (right) is shown
together with 3D view (middle panel) and a histogram from 4 independent gels (bottom panel).
doi:10.1371/journal.pone.0021977.g002
Table 1. List of proteins identified from the spots exhibiting $2.0-fold difference in expression between MB-231-Br and MB-231-Pa
cells.
Spot No Protein ID* Protein Name pI MW (KDa) Average Ratio P Value (FDR) MOWSE Score
848 gi|5031877 lamin B1 5.11 66.7 22.65 0.00087 1285
gi|5729877 heat shock 70 kDa protein 8 isoform 1 (HSPA8) 5.37 71.1 22.65 0.00087 913
gi|4529892 HSP70-2 5.48 70.3 22.65 0.00087 452
gi|4503841 ATP-dependent DNA helicase II, 70 kDa subunit 6.23 70.1 22.65 0.00087 176
878 gi|27262628 nuclear autoantigenic sperm protein isoform 2 (NASP) 4.26 85.5 2.02 0.0048 790
1094 gi|47115317 vimentin 5.09 53.6 2.24 0.00065 1402
1154 gi|340021 alpha-tubulin 4.94 50.8 2.02 0.00065 815
1062 gi|340021 alpha-tubulin 4.94 50.8 2.32 0.025 815
1945 gi|7765076 S3 ribosomal protein 9.7 26.9 2.76 0.0091 627
gi|4504447 heterogeneous nuclear ribonucleoprotein A2/B1
"isoform A2 (hnRNPA2/B1)
8.67 36 2.76 0.0091 136
gi|4502599 carbonyl reductase 1 8.55 30.6 2.76 0.0091 113
2577 gi|5031851 stathmin 1 isoform a 5.76 17.3 2.03 0.0094 575
gi|4506679 ribosomal protein S10 10.15 18.9 2.03 0.0094 253
*Each Protein ID contains a hyperlink to MASCOT search results and MS/MS data.
doi:10.1371/journal.pone.0021977.t001
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Cell culture
MDA-MB-231 parental (MB-231-Pa) and MDA-MB-231 brain
seeking (MB-231-Br) cell lines [13] were kindly provided by Dr.
Toshiyuki Yoneda (University of Texas Health Science Center at
San Antonio, San Antonio, TX, USA). Cells were routinely
maintained in monolayer cultures using RPMI 1640 media
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine
serum (Hyclone Laboratories, Logan,. Utah), 2 mM L-glutamine
(Invitrogen), and 10 mg/ml Gentamicin (Abraxis Pharmaceutical
Products, Schaumburg, IL).
Protein isolation and labeling
The MB-231-Pa and MB-231-Br cells were washed twice with cell
wash solution (10 mM Tris-HCl, pH 8.0, 5 mM magnesium acetate).
Approximately 10
7 cells were extracted in 200 mL of the lysis buffer
( 7Mu r e a ,2Mt h i o u r e a ,4 %C H A P S ,3 0m MT r i s ,p H8 . 5 ) .T h e
crude cell homogenate was ground using disposable pellet pestles in
microtubes for 5 min and sonicated three times for 5 seconds on ice.
The protein extracts were clarified by centrifugation for 60 min at
12000 g and protein concentration was measured using 2-D Quant
Kit (GE Healthcare, Salt Lake City, Utah).
Quadruplicate samples (independent biological replicates derived
from individual cultures) were labeled with CyDye Fluor minimal dyes
(GE Healthcare) according to the manufacturer’s instructions. Equal
amounts of protein from each sample were combined to create an
internal standard, which was used throughout the entire series of
experiments. The pH of the samples was adjusted to pH 8.5. Protein
extracts (50 mg) were labeled with 400 pmol of CyDye on ice in dark
(Cy3 or Cy5 for MB-231-Pa and MB-231-Br samples, Cy2 for the
internal standard). The reaction was quenched for 10 min with 1 mLo f
10 mM L-lysine on ice in dark. The MB-231-Pa and MB-231-Br
samples were randomized between Cy3 and Cy5 to avoid any dye
biases.
2D-DIGE and Decyder analysis
An equal volume of 26IEF buffer (7 M Urea, 2 M Thiourea,
4% CHAPS, 130 mM DTT, 2% IPG buffer 3–11 NL) was added
to each labeled sample. Cy3 sample, Cy5 sample, and Cy2
internal standard sample were pooled and brought up to a final
volume of 350 mL with rehydration buffer (7 M Urea, 2 M
Thiourea, 4% CHAPS, 18 mM DTT, 2% IPG buffer 3–11 NL).
The first-dimension IEF was performed in an IPGphor IEF unit
(GE Healthcare) on 18 cm IPG strips pH 3–11 (GE Healthcare).
IEF was carried as followed: 30 V rehydration step for 12 h,
followed by 500 V for 1 h, 1,000 V for 1 h, 3 h linear increase to
8,000 V, and a 12,000 Vh hold at 8,000 V. The cysteine
sulfhydryls were reduced with 1.0% DTT and carbamidomethy-
lated with 2.5% iodoacetamide in equilibration buffer (6 M Urea,
75 mM Tris, 30% glycerol, and 2% SDS, pH 8.8). Second-
dimension SDS-PAGE was performed on 6–12% gradient gels
casted using Ettan DALTsix gradient maker (GE Healthcare) and
low fluorescence glass plates. Electrophoresis was carried out at
1 W/gel (10 mA/gel) for 1 h followed by 10 W/gel (40 mA/gel)
until completion using Ettan DALTsix electrophoresis unit (GE
Healthcare). Gels were scanned using an Ettan DIGE Imager (GE
Healthcare). The image and statistical analyses were performed
using DeCyder 7.0 (GE Healthcare) with the FDR mode for
multiple testing corrections.
Peptide extraction
A parallel preparative gel was stained with modified colloidal
Coomassie Blue G-250 [15]. The differentially expressed spots
designated by DeCyder analysis were identified on the preparative
gel and picked up by hand. The gel pieces were washed twice in
200 mL 200 mM NH4HCO3 with 30 min incubation at 37uC, then
dehydrated with 100% acetonitrile (ACN) for 5 min and dried in a
SpeedVac (LABCONCO, Kansas City, MO) for 10–15 min. The
gel pieces were preincubated with 15 mLo f2 0 mg/mL mass
spectrometrygrade trypsingold (Promega,Madison,WI)solutionat
room temperature for 1 h, then 40 mL digestion buffer (40 mM
NH4HCO3/10% ACN) was added and incubated overnight at
37uC. Peptides were extracted from the gel pieces by incubation in
50 mL 50% ACN/5%formic acid for 1 h at 37uC. The liquid phase
was extracted and evaporated using SpeedVac.
Figure 3. Western blot analysis of the proteins differentially
expressed between MB-231-Pa and MB-231-Br cells. Whole-cell
lysates containing 50 mg of total cellular protein from MB-231-Pa and
MB-231-Br were loaded, separated by PAGE, and blotted onto
nitrocellulose membranes. The indicated proteins were probed using
commercially available primary antibodies (see Materials and Methods
for detail) and visualized using corresponding HRP conjugated
secondary antibodies and ECL detection.
doi:10.1371/journal.pone.0021977.g003
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The peptides were resolved in 5% ACN/1% formic acid. An
aliquot (5–10 ml) of each digest was loaded onto a 5 mm6100 mm
i.d. C18 reverse-phase cartridge at 2 ml/min using a PAL robot
(Leap Technologies, Carrboro, NC). After washing the cartridge
for 5 min with 0.1% formic acid in ddH2O, the bound peptides
were flushed onto a 22 cm6100 mm i.d. C18 reverse-phase pulled
tip analytical column with a 25 min linear 5–50% ACN gradient
in 0.1% formic acid at 500 nl/min using an Eksigent nanopump
(Eksigent Technologies, Dublin, CA). The column was washed
with 90% ACN-0.1% formic acid for 15 min and then re-
equilibrated with 5% ACN-0.1% formic acid for 24 min. The
eluted peptides were passed directly from the tip into a modified
MicroIonSpray interface of an Applied Biosystems-MDS-Sciex
(Concorde, Ontario, Canada) 4000 Qtrap mass spectrometer. The
interface has been rebuilt in order to apply the electrospray voltage
through a liquid-liquid junction at the top of the column rather
than at the end of the column. This arrangement resulted in very
high chromatographic resolution by elimination of the post-
column dead volume. The IonSpray voltage was 2500 V and the
Figure 4. Major signaling network 1 associated with the proteins differentially expressed in MB-231-Br compared with MB-231-Pa
cells identified by the Ingenuity pathway analysis. The network consists of 35 nodes and includes 11 out of 12 differentially expressed proteins
(shaded green). Note the interactions of NASP, RPS10, HSPA8, and HSPA1B with TRAF6 (TNF receptor-associated factor 6), a key factor acting upon
the TNFa/TGFb signaling axis, as well as the involvement of NFKB-, HSP-70-, TP53-, and IFNc-associated pathways.
doi:10.1371/journal.pone.0021977.g004
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set at 12 psi and 5 psi, respectively. The interface heater
temperature was 160uC. Eluted peptides were subjected to a
survey MS scan to determine the top three most intense ions. A
second scan (the enhanced resolution scan) determined the charge
state of the selected ions. Finally, enhanced product ion scans were
carried out to obtain the tandem mass spectrum of the selected
parent ions (with the declustering potential raised to 100 V) over
the range from m/z 400–1500. Spectra were centroided and
de-isotoped by Analyst Software, version 1.42 (Applied Biosys-
tems, Foster City, CA). These tandem mass spectrometry data
were processed to provide protein identifications using an in-house
MASCOT search engine version 4.2 (Matrix Science, Boston,
MA) using the Human NCBInr protein database and one missed
protease cleavage site. Variable modifications were allowed for
oxidized methionines and a fixed modification for carbamido-
methylated cysteines. Significant proteins hits were any protein(s)
that had at least one individual peptide sequence score of .40.
Figure 5. Major signaling network 2 associated with the proteins differentially expressed in MB-231-Br compared with MB-231-Pa
cells. The network consists of 35 nodes and includes 10 out of 12 differentially expressed proteins (shaded green). Similarly to network 1, interactions
of NASP, RPS10, HSPA8, and HSPA1B with TRAF6 bring about the association with the TNFa/TGFb signaling axis. In addition, NFKB-, HSP-70-, and
IFNc-associated major signaling pathways are also involved with the network.
doi:10.1371/journal.pone.0021977.g005
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Cells from exponential cultures (1610
6) were lysed in 100 mLo f
CelLytic
TM M buffer with protein inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO). Protein concentrations were determined
using Protein Assay kit (Bio-Rad). Equal amounts of the protein
from each sample (50 mg) were resolved on a NuPAGE mini gel
(Invitrogen), and transferred to a nitrocellulose membrane
(Invitrogen). The following antibodies (Ab) were used to detect
the proteins of interest: Vimentin (R28) (Cell Signaling Technol-
ogy, Boston, MA) at 1:1000 dilution, alpha-tubulin (Cell Signaling
Technology) at 1:1000 dilution, stathmin (Cell Signaling Tech-
nology) at 1:1000 dilution, hnRNPA2/B1 (Cell Signaling
Technology) at 1:1000 dilution; HSPA8 (sc-137239, Santa Cruz
Biotechnology, Santa Cruz, CA) at 1:500 dilution; carbonyl
reductase 1 (Santa Cruz Biotechnology) at 1:500 dilution; nuclear
autoantigenic sperm protein (Abcam Ltd., Cambridge, CA) at
1:2000 dilution, and lamin B 1 (Abcam Ltd., Cambridge, CA) at
0.1 mg/ml in conjunction with corresponding HRP-conjugated
secondary antibodies and enhanced chemiluminescent (ECL)
detection.
Pathway analysis
The accession numbers of the identified proteins were uploaded
into the Ingenuity Pathway Analysis software version 7.6 (http://
www.ingenuity.com), protein-protein interaction networks were
generated and schematic displays elaborated to illustrate docu-
mented protein-protein interactions. Similarly, the accession
numbers of the proteins differentially expressed in 435-Br1 cells
Figure 6. Major signaling network 1 associated with the proteins differentially expressed in brain-targeting 435-Br1 cells compared
with parental MDA-MB-435 cells reported by the group of Dr. Sierra (Ref. [14]). The network consists of 35 nodes, includes 12 out of 19
differentially expressed proteins (shaded red), and involves TNFa/TGFb-, NFKB-, HSP-70-, and MAPK-associated major signaling pathways.
doi:10.1371/journal.pone.0021977.g006
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associated with brain relapse in breast cancer patients identified by
the group of Dr. Massague [2] were also uploaded into Ingenuity
Pathway Analysis software, and signaling networks associated with
these two sets of genes/proteins were generated. Subsequently,
signaling networks derived from these three sources and
potentially involved in breast cancer brain metastasis were
compared and merged using Ingenuity Pathway Analysis software.
In the process of IPA analysis, each network was assigned a P-score
[P-score=2log10 (P-value)] reflecting the probability of this network
being generated at random, whereby P-value was calculated as the
right-tailed sum of the hypergeometric distribution (Fisher’s exact
test). That is, if the network has a P-score of 10, the odds of this
network being generated at random are less than 1 out of 10
10.
Results and Discussion
2D-DIGE analysis of MB-231-Br and MB-231-Pa cell lines
To identify proteins differentially expressed in breast cancer
MB-231-Br compared with MB-231-Pa cell line, we performed
2D-DIGE analysis using cyanine dye (CyDye) protein labeling.
This technology, based on differential labeling of proteins with
Figure 7. Major signaling network 2 associated with the proteins differentially expressed in brain-targeting 435-Br1 cells compared
with parental MDA-MB-435 cells (Ref. [14]). The network consists of 35 nodes, includes 5 out of 19 differentially expressed proteins (shaded
red), and involves TP53- and TNFa/TGFb-associated major signaling pathways.
doi:10.1371/journal.pone.0021977.g007
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variations. In our experiments, 4 individual protein samples from
MB-231-Pa as well as from MB-231-Br cells were prepared. The
samples were labeled with Cy3 or Cy5 dyes randomizing MB-231-
Pa and MB-231-Br samples between Cy3 and Cy5 to avoid any
dye biases. The pooled sample prepared by mixing equal amounts
of protein from each individual sample and labeled with Cy2 was
used as an internal standard throughout the series of experiments.
After 2D-DIGE separation, images of MB-231-Br and MB-231-Pa
expressed proteins were acquired from the same gel under
different wavelengths (Fig. 1, A and B). DeCyder 7.0 analysis
identified 2274–2607 protein spots by a volume of filter exclusion
of 30000 and matched 1843 spots between all 4 gels. Statistical
analysis using DeCyder 7.0 (Fig. 1, C) revealed 161 protein spots
consistently expressing $1.25-fold difference between MB-231-Br
and MB-231-Pa cells (p,0.05, t-test with FDR correction), 7 spots
consistently expressing $2.0-fold difference between MB-231-Br
and MB-231-Pa cells (p,0.05, t-test with FDR correction), and
only 2 spots consistently expressing $2.5-fold difference between
MB-231-Br and MB-231-Pa cells (p,0.05, t-test with FDR
correction). The seven spots exhibiting $2.0-fold difference
between the two cell lines were used for further analysis in this
study (Fig. 1, D). Compared with MB-231-Pa, 6 of these spots
were consistently up-regulated and 1 spot was consistently down-
regulated in MB-231-Br cells (Fig. 2).
Identification of differentially expressed proteins
To identify the protein spots, a pooled sample containing equal
amounts of total cellular proteins from MB-231-Br and MB-231-
Figure 8. Major signaling network 1 associated with the 17-gene breast carcinoma brain metastasis signature (Ref. [2]). The network
consists of 37 nodes, includes 10 out of 17 genes (shaded blue), and involves TNFa/TGFb-, NFKB-, MAPK-, PI3K/Akt-, and IFNa-associated major
signaling pathways.
doi:10.1371/journal.pone.0021977.g008
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colloidal Coomassie Blue G-250. The 7 differentially expressed
spots, identified as expressing $2.0-fold difference between MB-
231-Br and MB-231-Pa cells, were picked up by hand from this gel
and subjected to LC-MS/MS analysis as described in Materials and
Methods. After searching the NCBInr Human database using
Mascot software, tryptic peptides from these spots were matched
to 12 proteins with high MOWSE scores. The identified proteins
are listed in Table 1 together with their ID, name, calculated Mr,
calculated pI, average expression ratio, p-value (t-test with FDR
correction), and MOWSE scores. Some of the spots contained
more than one protein. In spot 848, four proteins were identified,
including lamin B1 (LMNB1), heat shock 70 kDa protein 8
isoform 1 (HSPA8), HSP70-2 (HSPA1B), ATP-dependent DNA
helicase II, 70 kDa subunit (XRCC6). In spot 1945, three proteins
were identified including S3 ribosomal protein (RPS3), heteroge-
neous nuclear ribonucleoprotein A2/B1 isoform A2
(hnRNPA2B1), and carbonyl reductase 1 (CBR1). In spot 2577,
two proteins were identified including stathmin 1 isoform A
(STMN1), and ribosomal protein S10 (RPS10). In addition, two
spots, 1062 and 1154, contained the same protein, alpha-tubulin
(TUBA1B), suggesting the existence of post-translational modifi-
Figure 9. Major signaling network 2 associated with the 17-gene breast carcinoma brain metastasis signature (Ref. [2]). The network
consists of 35 nodes, includes 6 out of 17 genes (shaded blue), and is mostly associated with TNFa/TGFb signaling axis.
doi:10.1371/journal.pone.0021977.g009
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motility. The MOWSE scores for all identified proteins were
markedly higher than the default Mascot threshold ranging from
113 to 1402 (Table 1).
It is interesting that 3 out of 12 differentially expressed proteins
represent different compartments of the cytoskeleton such as
nuclear matrix (lamin B1), microtubules (alpha-tubulin), and
intermediate filaments (vimentin); and 1 more protein (stathmin
1) is an important regulator of microtubule assembly suggesting
the potential importance of enhanced cytoskeletal dynamics
associated with tumor cell plasticity and motility for the process
of metastatic brain colonization. At the same time, the presence of
two heat shock proteins (HSPA8 and HSPA1B) may highlight the
importance of metastatic cell ability to manage environmental
stress.
Western blot analysis of differentially expressed proteins
To cross validate the differentially expressed proteins and assess
their specificity in MB-231-Pa and MB-231-Br, we performed
Western blot analysis for 8 out of 12 identified proteins, for which
suitable antibodies were available (Fig. 3). Western blot confirmed
marked overexpression of stathmin 1 (STMN1) and nuclear
autoantigenic sperm protein isoform 2 (NASP) in MB-231-Br
compared with MB-231-Pa. Other proteins, excluding
hnRNPA2/B1, showed the same expression trends revealed by
2D-DIGE analysis, although the differences in their expression
levels between MB-231-Br and MB-231-Pa on Western blots were
not as pronounced (Fig. 3). In the case of hnRNPA2/B1, Western
blot analysis showed results opposite to those revealed by 2D-
DIGE (Fig. 3). We speculate that some inconsistencies between
2D-DIGE and immunoblotting results could be due at least in part
because many proteins exist in several charge isoforms, which are
resolved on 2D gels, but appear as single bands on Western blots.
In addition, the immunoblotting results could be affected
significantly by the specificities and sensitivities of the antibodies.
Signaling networks associated with the proteins
differentially expressed in MB-231-Br cells
To reveal signal transduction pathways and/or signaling
networks associated with the proteins differentially expressed in
MB-231-Br cells, the identified 12 proteins were imported into the
Ingenuity pathway analysis (IPA) software. According to the IPA
knowledge base, 3 signaling networks, 2 major ones comprised of
35 nodes each and 1 minor comprised of 12 nodes, were associated
with this set of proteins. Network 1 (Fig. 4) included 11 out of the
12 differentially expressed proteins (P-score=30) and involved
TNFa/TGFb-, NFKB-, HSP-70-, TP53-, and IFNc-associated
major signaling pathways. Network 2 (Fig. 5) included 10 out of
the 12 differentially expressed proteins (P-score=28) and involved
TNFa/TGFb-, NFKB-, HSP-70-,and IFNc-associated major
signaling pathways. The minor network 3 (Fig. S1, A) included
only 2 out of the 12 differentially expressed proteins (P-score=5)
and was associated mostly with lamin/vimentin interactions.
Comparison with biological pathways associated with
breast carcinoma brain metastasis protein/gene
signatures reported in the literature
Recently, using a similar approach (2D-DIGE followed by MS
analysis), the group of Dr. Angels Sierra identified a set of 19
proteins differentially expressed in brain-targeting 435-Br1 cells
compared with parental MDA-MB-435 cells [14]. Between the
two sets of brain-metastasis-associated proteins (MB-231-based
identified by our group in this study and MB-435-based reported
by the group of Dr. Sierra [14]) only 2 out of 31 proteins, HSPA8
and vimentin, were the same. Thus, to estimate the likelihood of
the occurrence of this overlap by chance, we carried out the
hypergeometric distribution test [16]. The results of this analysis
demonstrated that it is highly unlikely (probability .95%) that the
2-protein overlap found between the two sets occurred by chance
(p,0.05). Next, to reveal the key signaling pathways or networks
related to the set of brain metastasis-associated proteins identified
by the group of Dr. Sierra using MDA-MB-435-based experi-
mental system, we imported the list of these 19 proteins into the
IPA software. The IPA analysis revealed 3 signaling networks (2
major and 1 minor) associated with this set of proteins. Network 1
(Fig. 6) included 12 out of 19 differentially expressed proteins (P-
score=28) and involved TNFa/TGFb-, NFKB-, HSP-70-, and
MAPK-associated major signaling pathways. Network 2 (Fig. 7)
included 5 out of 19 differentially expressed proteins (P-score=10)
and involved TP53-, and TNFa/TGFb-associated major signaling
pathways. The minor network 3 included only 1 out of 19
differentially expressed proteins, RIN3 (Fig. S1, B).
Recently, in a series of reports, the group of Dr. Joan Massague
identified genes and proteins involved in breast cancer metastasis
to lung [17,18], bones [17,19], and brain [2]. In the latter paper,
they reported a 17-gene signature associated with breast
carcinoma brain metastasis, which was developed based on gene
expression microarray analysis of 368 clinically annotated breast
tumors with documented brain relapse [2]. Analyzing this 17-gene
signature using the IPA software also retrieved 3 signaling
networks (2 major and 1 minor). Ten out of 17 genes were
present in network 1 (Fig. 8) involving TNFa/TGFb-, NFKB-,
MAPK-, PI3K/Akt-, and IFNa-associated major signal transduc-
tion pathways (P-score=28). Network 2 (Fig. 9) included 6 out of
Table 2. Major signal transduction pathways involved with signaling networks associated with three breast carcinoma brain
metastasis signatures.
Major Pathways Involved
Major Network HSP-70 NFKB TP53 TNFa/TGFb MAPK Akt IFNa/c
MB-231-Br Network 1 ++ + + +
MB-231-Br Network 2 ++ + +
435-Br1 Network 1 ++ + +
435-Br1 Network 2 ++
17-Gene Classifier Network 1 ++ + + +
17-Gene Classifier Network 2 +
doi:10.1371/journal.pone.0021977.t002
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TGFb signaling axis. The minor network 3 (Fig. S1, C) comprised
of only 3 nodes included 1 out of 17 genes, COL13A1.
Remarkably, even though only 2 out of 31 proteins were in
common between the MDA-MB-231-based set of brain metastasis-
associated proteins identified in the present study and MB-435-based
set reported by the group of Dr. Sierra [14], and none of these
proteins were present in a 17-gene breast cancer brain relapse
signature published by the group of Dr. Massague [2], nonetheless
they all converged on signaling networks involving similar major
signal transduction pathways (Table 2). Of these signaling pathways,
those related to the TNFa/TGFb axis and NFkB were associated
Figure 10. Merged network combining major signaling networks associated with the proteins differentially expressed in MB-231-Br
compared with MB-231-Pa cells (shaded green) and brain-targeting 435-Br1 cells compared with parental MDA-MB-435 cells
(shaded red).
doi:10.1371/journal.pone.0021977.g010
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and TP53-related pathways were involved with signaling networks
associated with MDA-MB-231-, and MB-435-based signatures
( T a b l e2a n dF i g s .4 ,5 ,6 ,7 ) .M A P K - r e l a t e dp a t h w a y sw e r ei n v o l v e d
with networks associated with MB-435-based and 17-gene brain
metastasis signatures (Table 2 and Figs. 6 and 8). IFNa-o rI F N c-
related pathways were involved with networks associated with MDA-
MB-231-based and 17-gene brain metastasis signatures (Table 2 and
F i g s .4 ,5 ,a n d8 ) .A n dP I 3 K / A k t - r e l ated signaling was involved with
the 17-gene brain metastasis signature associated network 1 only
(Table 2 and Fig. 8).
Because the same principal signal transduction pathways such as
TNFa/TGFb,N F KB, HSP-70, TP53, and MAPK are associated
with the major signaling networks generated based on all 3
signatures, these networks are highly related and actually could be
merged with each-other (Figures 10 and 11). The fact that
integrated network analysis of the brain metastasis associated
signatures retrieved using different experimental systems and
approaches (2D-DIGE proteomics used on brain targeting cell
lines, or gene expression analysis of patient samples with
documented brain relapse) yields highly related signaling networks
associated with the differentially expressed proteins and/or genes,
suggests strongly that the involvement of these signaling networks
could be essential for a successful colonization of the brain by
metastatic breast carcinoma cells.
It is interesting, though, that within the networks associated with
three different signatures; the connection to the same major signal
transduction pathways is evoked by distinct differentially expressed
proteins or genes. For example, in MDA-MB-231-based networks
1 and 2 (Figs. 4 and 5 respectively), the association with the
TNFa/TGFb-related pathways is brought about through the
interactions of NASP, RPS10, HSPA8, and HSPA1B with TRAF6
(TNF receptor-associated factor 6), a key factor acting upon the
TNFa/TGFb signaling axis. In the MB-435-based network 2
(Fig. 7), the involvement of the TNFa/TGFb signaling axis is
associated with RPSA, GLO1, and CTSD interactions with TNF
as well as CTSD and KRT1 interactions with TGFB1. Finally, in
the 17-gene brain metastasis signature associated networks 1 and 2
(Figs. 8 and 9 respectively), the involvement of the TNFa/TGFb
signaling axis is evoked via the interactions of 2 proteins (LTBP1,
MMP1) with TGFb as well as by interactions between PTGS2,
HBEGF, and TNFSF10 in network 1 (Fig. 8); whereas interactions
Figure 11. Merged network combining major signaling networks associated with the proteins differentially expressed in brain-
targeting 435-Br1 cells compared with parental MDA-MB-435 cells (shaded red) and 17-gene breast carcinoma brain metastasis
signature (shaded blue).
doi:10.1371/journal.pone.0021977.g011
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B4GALT6, and SEPP1 with TNF bring up TNFa/TGFb
signaling axis in network 2 (Fig. 9).
Likewise, the involvement of the NFKB pathway is brought
about by the interactions of HSPA8 and XRCC6 with NFKBIA in
MB-231-based networks 1 and 2 (Figs. 4 and 5 respectively),
whereas in MB-435-based network 1 and 17-gene brain metastasis
signature associated network 1 (Figs. 6 and 8 respectively), the
NFKB pathway involvement is evoked by PRDX4 and VIM (MB-
435-based network 1), or PELI1 and RARRES3 (17-gene brain
metastasis signature associated networks 1) interactions with NFKB
complex.
Similarly, the TP53 pathway in MB-231-based network 1 (Fig. 4)
is brought about by HSPA8, HNRNPA2B1, and XRCC6
interactions with TP53, while in MB-435-based network 2
(Fig. 7) it is associated with TP53 interactions with RAD50,
RPSA, and CTSD.
All these examples demonstrate that, whereas highly related
signaling networks involving similar major signal transduction
pathways are associated with brain colonization by cancer cell
lines and primary tumors, different cancer cells may exploit
distinct avenues to achieve the same goal, i.e. engage signaling
pathways and networks essential for a successful organ-specific
colonization of the brain by metastatic breast carcinoma cells. The
availability of multiple alternative routes for activating these
pathways means that, when a single protein or gene is targeted
therapeutically to block a certain metastasis-associated pathway,
the success (as is often the case) is likely to be transient. Due to
their robustness and plasticity, metastatic cancer cells will adapt to
changing conditions and use available alternative routes to
circumvent the roadblocks imposed by therapeutic interventions
and activate signaling network required for them to continue
thriving in distant organ milieu. Thus, creating new treatment
paradigms targeting these networks in their entirety, rather than
single proteins, could be necessary for controlling and treating
efficiently breast carcinoma brain metastases.
Supporting Information
Figure S1 Minor signaling networks associated with
three breast cancer brain metastasis signatures. A,
Minor signaling network 1 associated with the proteins differen-
tially expressed in MB-231-Br compared with MB-231-Pa cells
(shaded green). B, Minor signaling network 1 associated with the
proteins differentially expressed in brain-targeting 435-Br1 cells
compared with parental MDA-MB-435 cells (shaded red). C,
Minor signaling network 1 associated with the 17-gene breast
carcinoma brain metastasis signature (shaded blue).
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